Literature DB >> 24649153

Expression of miR-486 is a potential prognostic factor after nephrectomy in advanced renal cell carcinoma.

Keisuke Goto1, Naohide Oue2, Shunsuke Shinmei1, Kazuhiro Sentani2, Naoya Sakamoto2, Yutaka Naito2, Tetsutaro Hayashi3, Jun Teishima3, Akio Matsubara3, Wataru Yasui2.   

Abstract

Renal cell carcinoma is the most frequently occurring neoplasm in the adult kidney, leading to poor prognosis. Therefore novel biomarkers are required for the prediction of early metastasis following nephrectomy. The aim of the present study was to investigate whether or not expression levels of miR-486, detected in RNA isolated from formalin-fixed paraffin-embedded tissue sections, can predict prognosis for patients with renal cell carcinoma (RCC). Expression levels of miR-486 were measured by quantitative reverse transcriptase-polymerase chain reaction in 150 RCC cases. Expression of miR-486 in RCC samples was ∼2.7-fold higher than in corresponding non-neoplastic kidney samples (P<0.0001). In stage III and IV RCC cases (n=46), a high miR-486 expression in tumors was associated with worse cancer-specific mortality, independent of clinical covariates, including TNM staging (P=0.0064). In addition, miR-486 expression tended to be associated with cancer-specific mortality in stage III and IV RCC patients who were not treated with interferon-α (Kaplan-Meier analysis, n=14, P=0.0574). These results suggest that miR-486 is a promising biomarker to identify poor prognosis in RCC patients. As expression of miR-486 was measured from formalin-fixed paraffin-embedded (FFPE) samples, this study demonstrated that measurement of miR-486 may be readily translated into clinical applications.

Entities:  

Keywords:  miR-486; miRNA; prognosis; renal cell carcinoma

Year:  2012        PMID: 24649153      PMCID: PMC3956263          DOI: 10.3892/mco.2012.46

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  18 in total

Review 1.  Effect of fixatives and tissue processing on the content and integrity of nucleic acids.

Authors:  Mythily Srinivasan; Daniel Sedmak; Scott Jewell
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

2.  Specific overexpression of OLFM4(GW112/HGC-1) mRNA in colon, breast and lung cancer tissues detected using quantitative analysis.

Authors:  Saori Koshida; Daisuke Kobayashi; Ryosuke Moriai; Naoki Tsuji; Naoki Watanabe
Journal:  Cancer Sci       Date:  2007-03       Impact factor: 6.716

Review 3.  Gene silencing by microRNAs: contributions of translational repression and mRNA decay.

Authors:  Eric Huntzinger; Elisa Izaurralde
Journal:  Nat Rev Genet       Date:  2011-02       Impact factor: 53.242

4.  Regulation of PI3-kinase/Akt signaling by muscle-enriched microRNA-486.

Authors:  Eric M Small; Jason R O'Rourke; Viviana Moresi; Lillian B Sutherland; John McAnally; Robert D Gerard; James A Richardson; Eric N Olson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-08       Impact factor: 11.205

5.  Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis.

Authors:  Tetsuya Ueda; Stefano Volinia; Hiroshi Okumura; Masayoshi Shimizu; Cristian Taccioli; Simona Rossi; Hansjuerg Alder; Chang-gong Liu; Naohide Oue; Wataru Yasui; Kazuhiro Yoshida; Hiroki Sasaki; Sachiyo Nomura; Yasuyuki Seto; Michio Kaminishi; George A Calin; Carlo M Croce
Journal:  Lancet Oncol       Date:  2009-12-18       Impact factor: 41.316

6.  Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways.

Authors:  Michael A Crackower; Gavin Y Oudit; Ivona Kozieradzki; Renu Sarao; Hui Sun; Takehiko Sasaki; Emilio Hirsch; Akira Suzuki; Tetsuo Shioi; Junko Irie-Sasaki; Rajan Sah; Hai-Ying M Cheng; Vitalyi O Rybin; Giuseppe Lembo; Luigi Fratta; Antonio J Oliveira-dos-Santos; Jeffery L Benovic; C Ronald Kahn; Seigo Izumo; Susan F Steinberg; Matthias P Wymann; Peter H Backx; Josef M Penninger
Journal:  Cell       Date:  2002-09-20       Impact factor: 41.582

7.  Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer.

Authors:  Zhibin Hu; Xi Chen; Yang Zhao; Tian Tian; Guangfu Jin; Yongqian Shu; Yijiang Chen; Lin Xu; Ke Zen; Chenyu Zhang; Hongbing Shen
Journal:  J Clin Oncol       Date:  2010-03-01       Impact factor: 44.544

8.  MicroRNA expression profiles classify human cancers.

Authors:  Jun Lu; Gad Getz; Eric A Miska; Ezequiel Alvarez-Saavedra; Justin Lamb; David Peck; Alejandro Sweet-Cordero; Benjamin L Ebert; Raymond H Mak; Adolfo A Ferrando; James R Downing; Tyler Jacks; H Robert Horvitz; Todd R Golub
Journal:  Nature       Date:  2005-06-09       Impact factor: 49.962

9.  Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators.

Authors: 
Journal:  Lancet       Date:  1999-01-02       Impact factor: 79.321

10.  Serum olfactomedin 4 (GW112, hGC-1) in combination with Reg IV is a highly sensitive biomarker for gastric cancer patients.

Authors:  Naohide Oue; Kazuhiro Sentani; Tsuyoshi Noguchi; Shinya Ohara; Naoya Sakamoto; Tetsutaro Hayashi; Katsuhiro Anami; Junichi Motoshita; Masanori Ito; Shinji Tanaka; Kazuhiro Yoshida; Wataru Yasui
Journal:  Int J Cancer       Date:  2009-11-15       Impact factor: 7.396

View more
  12 in total

1.  Tissue-Specific MicroRNA Expression Patterns in Four Types of Kidney Disease.

Authors:  Maria Angeles Baker; Seth J Davis; Pengyuan Liu; Xiaoqing Pan; Anna Marie Williams; Kenneth A Iczkowski; Sean T Gallagher; Kaylee Bishop; Kevin R Regner; Yong Liu; Mingyu Liang
Journal:  J Am Soc Nephrol       Date:  2017-06-29       Impact factor: 10.121

2.  MicroRNA-495 suppresses human renal cell carcinoma malignancy by targeting SATB1.

Authors:  Cai Lv; Zhiming Bai; Zhenxiang Liu; Pengcheng Luo; Jie Zhang
Journal:  Am J Transl Res       Date:  2015-10-15       Impact factor: 4.060

3.  The transcribed-ultraconserved regions in prostate and gastric cancer: DNA hypermethylation and microRNA-associated regulation.

Authors:  K Goto; S Ishikawa; R Honma; K Tanimoto; N Sakamoto; K Sentani; N Oue; J Teishima; A Matsubara; W Yasui
Journal:  Oncogene       Date:  2015-12-07       Impact factor: 9.867

4.  MiRNA-107 enhances chemosensitivity to paclitaxel by targeting antiapoptotic factor Bcl-w in non small cell lung cancer.

Authors:  Chaojing Lu; Zhibing Xie; Qingzhen Peng
Journal:  Am J Cancer Res       Date:  2017-09-01       Impact factor: 6.166

5.  Expression and prognostic value of miR-486-5p in patients with gastric adenocarcinoma.

Authors:  Hui Chen; Chuanli Ren; Chongxu Han; Daxin Wang; Yong Chen; Deyuan Fu
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

6.  Diagnostic and prognostic accuracy of miR-21 in renal cell carcinoma: a systematic review protocol.

Authors:  Arezoo Rasti; Mitra Mehrazma; Zahra Madjd; Abbas Ali Keshtkar; Raheleh Roudi; Sadegh Babashah
Journal:  BMJ Open       Date:  2016-01-04       Impact factor: 2.692

7.  miR-486-5p suppresses prostate cancer metastasis by targeting Snail and regulating epithelial-mesenchymal transition.

Authors:  Xiaoguang Zhang; Tong Zhang; Kuo Yang; Minghao Zhang; Keming Wang
Journal:  Onco Targets Ther       Date:  2016-11-08       Impact factor: 4.147

Review 8.  MicroRNAs as prognostic molecular signatures in renal cell carcinoma: a systematic review and meta-analysis.

Authors:  Liangyou Gu; Hongzhao Li; Luyao Chen; Xin Ma; Yu Gao; Xintao Li; Yu Zhang; Yang Fan; Xu Zhang
Journal:  Oncotarget       Date:  2015-10-20

9.  miR-486 functions as a tumor suppressor in esophageal cancer by targeting CDK4/BCAS2.

Authors:  Baoping Lang; Song Zhao
Journal:  Oncol Rep       Date:  2017-11-01       Impact factor: 3.906

10.  Urinary exosomes reveal protein signatures in hypertensive patients with albuminuria.

Authors:  Laura Gonzalez-Calero; Paula J Martínez; Marta Martin-Lorenzo; Montserrat Baldan-Martin; Gema Ruiz-Hurtado; Fernando de la Cuesta; Eva Calvo; Julian Segura; Juan Antonio Lopez; Jesús Vázquez; Maria G Barderas; Luis M Ruilope; Fernando Vivanco; Gloria Alvarez-Llamas
Journal:  Oncotarget       Date:  2017-07-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.